For the Inventor, By the Inventor

Enter assignee name

Lexington, MA, United States of America

Concert Pharmaceuticals, Inc.

USPTO Granted Patents = 136

CIPO Patents = 5

EPO Patents = 56

Forward Citations = 1,281

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

Roger D Tung (74 out of 126 patents)

Scott L Harbeson (47 out of 60 patents)

Julie Fields Liu (36 out of 41 patents)

4. Craig E Masse (17 out of 72 patents)

5. I Robert Silverman (11 out of 14 patents)

6. Adam J Morgan (9 out of 13 patents)

7. Philip B Graham (9 out of 9 patents)

8. Rose A Persichetti (5 out of 6 patents)

9. Bhaumik Pandya (4 out of 12 patents)

10. Emerich Eisenreich (2 out of 5 patents)

11. Xuejun Karl Liu (2 out of 5 patents)

12. Robert Silverman (2 out of 2 patents)

13. Ian Robert Silverman (2 out of 2 patents)

14. Xuejun Tang (2 out of 3 patents)

15. Andrew D Jones (2 out of 12 patents)

Core Competencies:

Morphinan Compounds

Deuterated EPI-743

Deuterated Idebenone

Deuterated JAK Inhibitors

4-Hydroxybutyric Acid Analogs

UDP-Glucose: N-Acyl-Sphingosine Glucosyltransferase Inhibitors

Substituted Triazolobenzodiazepines

Deuterated Rigosertib

Cholesterol Ester Transfer Protein Inhibitors

Deuterated Analogues of D-Serine

Deuterated Pyrazino[2,1-a]Isoquinoline Compounds

136 patents: Sort by Forward Citations

1. 12319954 - Morphinan compounds (2025-06-03),

2. 11473123 - Morphinan compounds (2022-10-18),

3. 11267777 - Deuterated EPI-743 (2022-03-08),

4. 11161798 - 4-hydroxybutyric acid analogs (2021-11-02),

5. 10843993 - Deuterated idebenone (2020-11-24),

6. 10842792 - Deuterated baricitinib (2020-11-24),

7. 10813926 - Morphinan compounds (2020-10-27),

8. 10683305 - Deuterated OTX-015 (2020-06-16),

9. 10668036 - Deuterated analogs of D-serine and uses thereof (2020-06-02),

10. 10561659 - Treatment of hair loss disorders with deuterated JAK inhibitors (2020-02-18),

11. 10532971 - 4-hydroxybutyric acid analogs (2020-01-14),

12. 10442761 - Deuterated GFT-505 (2019-10-15),

13. 10406155 - Morphinan compounds (2019-09-10),

14. 10385042 - Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase (2019-08-20),

15. 10357499 - Substituted triazolobenzodiazepines (2019-07-23),

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with serious diseases. With a proprietary deuterium chemistry approach, Concert aims to optimize existing drugs and create new chemical entities with enhanced therapeutic benefits. By leveraging its expertise in drug design, Concert is committed to improving the lives of patients through the development of novel medicines.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

136 Patents

#7 in Lexington, MA

#148 in Massachusetts

#2,746 in US

#5,783 in the World

Lexington, MA, United States of America

Concert Pharmaceuticals, Inc.

Forward Citations = 1,281

29 inventors:

Roger D Tung (74 out of 126 patents)

Scott L Harbeson (47 out of 60 patents)

Julie Fields Liu (36 out of 41 patents)

4. Craig E Masse (17 out of 72 patents)

5. I Robert Silverman (11 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…